期刊文献+

气相色谱法测定1-(5-溴-1H-吲唑-1-基)乙酮

Determination of 1-(5-Bromo-1H-Indazol-1-yl)Ethanone by Gas Chromatography
下载PDF
导出
摘要 建立了测定1-(5-溴-1H-吲唑-1-基)乙酮纯度的气相色谱法。采用DB–5型色谱柱,程序升温,火焰光度检测器,外标法定量,1-(5-溴-1H-吲唑-1-基)乙酮在100~1000 mg/L范围内内线性关系良好,检出限为0.01 mg/L。测定结果的相对标准偏差为1.67%~1.89%(n=5),样品加标回收率为98.1%~107.9%。用该方法测定了自制的1-(5-溴-1H-吲唑-1-基)乙酮样品的纯度。该测定方法准确度高、专属性较强且灵敏度较高,适用于1-(5-溴-1H-吲唑-1-基)乙酮的质量控制。 The method was set up to determine the purity of 1-(5-bromo-1H-indazol-1-yl)ethanone by gas chromatography. DB–5 column was used with program temperatured, FPD as the detector and external standard method was used as the quantitative method. 1-(5-bromo-1H-indazole-1-yl)ethanone had good linear relationship in the concentration range of 100–1 000 mg/L, the detection limit was 0.01 mg/L. RSD were 1.67%–1.89%(n=5), and the recoveries were 98.1%–107.9%. Self-made 1-(5-bromo-1H-indazol-1-yl)ethanone sample purity was determined by this method. The method is accurate, specific and high sensitive, it can be used for quality control of 1-(5-bromo-1H-indazol-1-yl)ethanone.
出处 《化学分析计量》 CAS 2015年第2期26-28,共3页 Chemical Analysis And Meterage
基金 国家"十二五"科技支撑计划项目(2012BAK25B03)
关键词 1-(5-溴-1H-吲唑-1-基)乙酮 气相色谱法 含量测定 1-(5-bromo-1H-indazol-1-yl)ethanone gas chromatography content determination
  • 相关文献

参考文献8

  • 1Demetrio R, Benedetta M, Stella C A, et al. Synthesis and antiproliferativeactivity of 3-amino-N-phenyl- 1H-indazole- 1- carboxamides [ J ]. European Journal of Medicinal Chemistry, 2009,44(1): 165-178.
  • 2Bender S L, Kania R S, Borchardt A J, et al. Indazole compounds and pharmaceutical compo-sitions for inhibiting protein kinases, and methods for their use [ P ]. American Patent,7141587,2006- 11-28.
  • 3Rodgers J D, Sun J H, Teleha C A, et al. Efficient Synthesis of 5-(Bromolmethyl)-and 5-(Am-inomethyl)-l-THP-Indazole [ J ]. Journal of Organic Chemistry, 1997,62(16): 5 627-5 629.
  • 4吴仲可,张萍华,陶宇梁,费雪南.一种新型生长物质——吲唑酯(Ethychlozate)的分析[J].上海交通大学学报(农业科学版),1990,17(3):195-201. 被引量:1
  • 5Ismall H, Hamed E F, Ehab E, et al. Development and application of a validated stability-indicating HPLC method for simultaneous determination of granisetron hydrochloride, benzyl alcohol and their main degradation products in parenteral dosage forms [ J ]. Talanta,2010,82: 184-195.
  • 6Shuko T, Aiko F, Ken-ichi S, et al. Determination of a novel calmodulin antagonist, 3- [2- [ 4-(3-chloro-2-methylphenyl)- 1- piperazinyl ] ethyl-5,6-dimethoxy- 1-(4-imidazolylmethyl)- 1 H-indazole dihydrochloride 3.5 hydrate, DY-9760e, in human plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection [ J ]. Journal of Chromatography B, 1999,734: 39-45.
  • 7Ismall H, Hamed E F, Ehab E, et al. Development and application of a validated stability-indicating high-performance liquid chromatographic method using photodiode array detection forsimultaneous determination of granisetron, methylparaben, propylparaben, sodium benzoate, and their main degradation products in oral pharmaceutical preparations [ J ]. Journal of AOAC International, 2011,94(5): 1 447-1 462.
  • 8武玉洁,王夙博,袁天翊,李人则,焦晓臻,谢平,方莲花,杜冠华.新型Rho激酶抑制剂DL0805-1大鼠体内药代动力学初步研究[J].中国药理学通报,2014,30(8):1171-1174. 被引量:3

二级参考文献9

  • 1Gong L L, Fang L H, Peng J H,et al. Integration of virtual screening with high-throughput screening for the identification of novel Rho-kinase I inhibitors[J]. J Biotechnol, 2010, 145(3):295-303.
  • 2方莲花,谢 平,杜冠华,等.《吲唑类化合物﹑其制备方法及其药物用途》:中国, CN201210172191.0[P]. 2012-5-29.
  • 3Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension[J]. Nature, 1997, 389(6654):990-4.
  • 4Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology[J]. Circ Res, 2006, 98(3):322-34.
  • 5Liu Y, Suzuki Y J, Day R M, Fanburg B L. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin[J]. Circ Res, 2004, 95(6):579-86.
  • 6Surma M, Wei L, Shi J. Rho kinase as a therapeutic target in cardiovascular disease[J]. Future Cardiol, 2011, 7(5): 657-71.
  • 7Iwakubo M, Takami A, Okada Y. Design and synthesis of Rho kinase inhibitors(II)[J]. Bioorg Med Chem, 2007, 15(1): 350-64.
  • 8Oh K S, Oh B K, Park C H, et al. Cardiovascular effects of a novel selective Rho kinase inhibitor, 2-(1H-indazole-5-yl)amino-4-methoxy-6-piperazino triazine(DW1865)[J]. Eur J Pharmacol, 2013, 702(1-3): 218-26.
  • 9Goodman K B, Cui H, Dowdell S E, et al. Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors[J]. J Med Chem, 2007, 50(1): 6-9.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部